Bezlotoxumab (Zinplava) is a targeted therapy for reducing recurrence of Clostridium difficile infection.
Compound: human monoclonal IgG1/kappa antibody
Target: C. difficile toxin B
Dose: 10 mg per kg body weight
Dosage form (concentration): 25 mg/mL in single dose vial (1,000 mg in 40 mL)
Administration: intravenous infusion over 60 minutes
Concentration for infusion (in 0.9% sodium chloride or 5% dextrose): 1-10 mg/mL (dilution factor 2.5 to 25 fold)
Elimination half-life: about 19 days
Indications and usage:
(1) The patient must be >= 18 years of age.
(2) The patient has or is at high risk for recurrence of Clostridium difficile infection.
(3) The patient is concurrently receiving appropriate antibiotic therapy against Clostridium difficile.
Limitations:
(1) cost: less expensive alternatives may exist
To read more or access our algorithms and calculators, please log in or register.
Specialty: Infectious Diseases, Pharmacology, clinical, Gastroenterology